Gainers

• AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion.
• Agape ATP (NASDAQ:ATPC) shares moved upwards by 27.77% to $3.22. The market value of their outstanding shares is at $2.5 million.
• Liminatus Pharma (NASDAQ:LIMN) shares increased by 23.23% to $0.14. The company's market cap stands at $7.6 million.
• GH Research (NASDAQ:GHRS) shares rose 17.75% to $31.7. The market value of their outstanding shares is at $1.8 billion.
• Virax Biolabs Group (NASDAQ:VRAX) stock increased by 16.23% to $4.01. The market value of their outstanding shares is at $2.7 million.
• Kairos Pharma (AMEX:KAPA) stock moved upwards by 12.16% to $0.36. The market value of their outstanding shares is at $6.8 million.

Losers

• CDT Equity (NASDAQ:CDT) stock decreased by 19.8% to $0.28 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 million. As per the press release, Q1 earnings came out yesterday.
• Decoy Therapeutics (NASDAQ:DCOY) shares declined by 12.46% to $5.41. The market value of their outstanding shares is at $3.2 million.
• Entera Bio (NASDAQ:ENTX) shares declined by 11.24% to $1.58. The company's market cap stands at $87.6 million.
• GlucoTrack (NASDAQ:GCTK) stock fell 10.59% to $0.47. The company's market cap stands at $3.3 million.
• Exicure (NASDAQ:XCUR) stock fell 10.5% to $1.45. The company's market cap stands at $10.3 million.
• Alpha Compute (NASDAQ:ALP) shares decreased by 10.04% to $0.29. The company's market cap stands at $7.5 million. As per the press release, FY earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.